WebDoctor Encyclopedia

Central nervous system

Haemangioblastoma (including von Hippel-Lindau disease)

Haemangioblastoma is a benign, blood vessel-rich tumour of the cerebellum, brainstem, spinal cord or retina. About 1 in 4 occur in von Hippel-Lindau disease. Surgery usually cures single tumours; people with VHL need lifelong surveillance and may benefit from belzutifan.

Medically reviewed Last reviewed November 15, 2026

What is haemangioblastoma?

A haemangioblastoma (spelled hemangioblastoma in American English) is a benign, slow-growing tumour full of blood vessels. It grows in the central nervous system, most often in the cerebellum (the back part of the brain that controls balance), the brainstem or the spinal cord. It can also grow in the retina at the back of the eye.

Haemangioblastomas are not cancer and do not spread to other organs. The World Health Organization (WHO) classifies them as CNS WHO grade 1 (Louis et al., 2021). They can still cause serious problems, because they press on delicate brain and spinal cord tissue and often form fluid-filled cysts that are much bigger than the tumour itself.

They account for about 1-2.5% of brain tumours but are among the most common tumours of the cerebellum in adults.

About 3 in 4 haemangioblastomas are sporadic, meaning they occur by chance, usually as a single tumour in middle age. About 1 in 4 are part of von Hippel-Lindau (VHL) disease, an inherited condition in which people develop several tumours, often from their teens or twenties (Lonser et al., 2003).

Most haemangioblastomas are treated by surgery, which usually cures a single sporadic tumour. People with VHL need lifelong surveillance, and a newer tablet, belzutifan, can shrink VHL-related tumours (Jonasch et al., 2021).

1. Key facts at a glance

Feature Details
Type of tumour Benign, blood vessel-rich tumour of the brain, spinal cord or retina
WHO grade CNS WHO grade 1
How common About 1-2.5% of brain tumours
Typical age Sporadic: 40s-60s; VHL-related: often teens to 30s
Common sites Cerebellum, spinal cord, brainstem, retina
Link with VHL About 1 in 4 people with a haemangioblastoma have VHL
Main treatment Surgery; radiosurgery or belzutifan in selected cases
Outlook Excellent for sporadic tumours; VHL needs lifelong care

2. Causes and risk factors

The VHL gene

Almost all haemangioblastomas involve the VHL gene. This gene normally acts as a brake on proteins called hypoxia-inducible factors (HIFs), which tell cells to grow new blood vessels when oxygen is low.

When VHL stops working, HIFs build up, especially HIF-2 alpha. The cells then behave as if they are short of oxygen and produce signals such as VEGF and erythropoietin. This explains why the tumours are so full of blood vessels and why some people develop a high red blood cell count (Maher et al., 2011).

Type Cause Features
Sporadic Both copies of VHL damaged in the tumour only Usually a single tumour in middle age; not inherited
VHL-related One faulty copy inherited in every cell; the second copy is damaged later Often multiple tumours at a younger age; can be passed on

Von Hippel-Lindau disease

VHL disease is an inherited condition that affects about 1 in 36,000 people. It is passed on in an autosomal dominant way, which means each child of an affected parent has a 1 in 2 chance of inheriting it. About 1 in 5 people with VHL have a new gene change that was not inherited from a parent.

VHL-related condition Approximate frequency in VHL
Haemangioblastomas of the brain and spinal cord 60-80%
Retinal haemangioblastomas About 60%
Kidney cysts and clear cell kidney cancer Up to 70%
Phaeochromocytoma 10-20%
Pancreatic cysts and neuroendocrine tumours Cysts common; neuroendocrine tumours 10-17%
Endolymphatic sac tumours (inner ear) About 10%
Cysts of the epididymis or broad ligament Common

Anyone diagnosed with a haemangioblastoma, especially if young or with more than one tumour, should be offered genetic testing for VHL.

3. How does it look

On MRI scans

Feature Typical appearance
Classic pattern A large fluid-filled cyst with a small, brightly enhancing nodule in its wall
Solid type A solid, strongly enhancing tumour without a cyst
Blood vessels Enlarged blood vessels around the tumour, seen as dark “flow voids”
Spinal cord tumours A small enhancing nodule with a long fluid cavity (syrinx) in the cord
Swelling Fluid and swelling around the tumour in some cases

The cyst is often what causes symptoms. A tumour nodule of a few millimetres can produce a cyst several centimetres across.

In the eye

A retinal haemangioblastoma looks like a red-orange round spot on the retina, fed by a widened artery and drained by a widened vein. Small tumours may only be seen with special eye photography.

Under the microscope

Feature Description
Blood vessels A dense network of small, thin-walled capillaries
Stromal cells Large tumour cells with pale, bubbly (lipid-filled) cytoplasm between the vessels
Behaviour Few dividing cells; no invasion
Special stains Stromal cells positive for inhibin and S100; usually negative for keratin, EMA and CD10, which helps tell it apart from spread of clear cell kidney cancer

4. Symptoms

Symptoms depend on where the tumour is and the size of its cyst. Small tumours often cause no symptoms and are found on screening scans in people with VHL.

Cerebellar tumours

  • Headache, often worse in the morning
  • Nausea and vomiting
  • Unsteadiness and poor balance
  • Clumsiness of the arms or legs
  • Dizziness
  • Blurred or double vision from raised pressure inside the head

Spinal cord tumours

  • Neck or back pain
  • Numbness or tingling in the arms or legs
  • Weakness of the limbs
  • Loss of temperature or pain sensation with a syrinx
  • Bladder or bowel problems in advanced cases

Brainstem tumours

  • Swallowing problems
  • Hoarse voice
  • Facial numbness or weakness
  • Unsteady walking

Retinal tumours

  • Blurred vision
  • Distorted vision or a dark patch
  • Loss of vision if the retina becomes detached or swollen

Effects on the blood

About 5-20% of people develop polycythaemia, a high red blood cell count, because the tumour makes erythropoietin. This can cause headaches, flushing and a higher risk of blood clots.

When to seek medical advice

See a doctor about persistent morning headaches with vomiting, new unsteadiness, limb weakness or numbness, or vision changes. Seek urgent help for sudden severe headache, confusion or drowsiness.

5. Diagnosis

Test Purpose
Neurological examination Checks balance, strength, sensation and nerves
MRI of the brain and whole spine with contrast The main test; shows tumours and cysts
Dilated eye examination Looks for retinal haemangioblastomas
Blood count Checks for polycythaemia
Genetic testing for VHL Recommended for young people, those with multiple tumours or a family history
Abdominal imaging and metanephrine tests For people with VHL, to look for kidney, pancreatic and adrenal tumours
Angiography Sometimes before surgery to map blood supply

6. Treatment

Treatment depends on symptoms, size, growth and whether the person has VHL. Not every haemangioblastoma needs treatment straight away.

Sporadic haemangioblastoma

Treatment Notes
Surgery Complete removal of the tumour nodule usually cures a single sporadic tumour; the cyst then collapses
Stereotactic radiosurgery For small tumours that are hard to reach or when surgery is risky
Shunt or drain Occasionally needed to relieve raised pressure from blocked fluid flow

The surgeon removes the whole nodule in one piece, because cutting into it can cause heavy bleeding.

Haemangioblastomas in VHL

In VHL, tumours often grow in spurts with long quiet periods. Many never cause symptoms (Lonser et al., 2014). Treatment is therefore usually offered when a tumour causes symptoms or is growing quickly or forming a large cyst (Wanebo et al., 2003).

Treatment Notes
Active surveillance Regular MRI scans for symptom-free tumours
Surgery For symptomatic tumours or growing cysts
Stereotactic radiosurgery For small, solid tumours; less effective for tumours with cysts over time
Belzutifan A HIF-2 alpha inhibitor tablet for VHL-related CNS haemangioblastomas, kidney cancer and pancreatic neuroendocrine tumours not needing immediate surgery
Retinal treatment Laser therapy, freezing (cryotherapy) or other eye treatments

In the key trial, belzutifan shrank CNS haemangioblastomas in about 30% of people and retinal haemangioblastomas in nearly all eyes assessed (Jonasch et al., 2021). It is approved for VHL in the United States and Europe.

Side effects

Treatment Possible side effects
Brain or spinal surgery Headache, infection, bleeding, worsening balance or weakness (often temporary)
Radiosurgery Swelling around the tumour, headache, cyst growth
Belzutifan Anaemia (very common), tiredness, dizziness, shortness of breath, low oxygen levels; it can reduce the effect of hormonal contraception and may harm an unborn baby

7. Outlook (prognosis)

Situation Outlook
Single sporadic tumour, completely removed Excellent; usually cured with a normal life expectancy
Recurrence after complete removal Uncommon for sporadic tumours
VHL-related tumours New tumours develop over time; lifelong monitoring and repeated treatments may be needed

For people with VHL, the main threats to health over a lifetime are CNS haemangioblastomas and kidney cancer. Regular surveillance and timely treatment have greatly improved life expectancy and quality of life (Maher et al., 2011).

8. Follow-up and surveillance

After a sporadic tumour

An MRI scan a few months after surgery, then at intervals for several years, checks that the tumour has gone.

For people with VHL

International guidelines recommend a structured lifelong screening programme (Daniels et al., 2023).

Test Typical starting age and frequency
Eye examination From infancy (about age 1), every 1-2 years
MRI of the brain and spine From about age 11, every 2 years
Blood pressure and metanephrine tests From age 5, yearly
Abdominal MRI From age 15, every 2 years
Hearing test Every 2 years from about age 11; MRI of the inner ear if symptoms

Relatives of a person with VHL should be offered genetic testing, so that those who carry the gene change can start screening early.

What surgery involves

Stage What to expect
Before surgery MRI scans, sometimes angiography, and blood tests including a blood count
The operation General anaesthetic; the tumour is reached through an opening at the back of the skull or spine
Hospital stay Usually 4-7 days, starting with a night in intensive care or high-dependency care
Recovery Headache, neck stiffness and tiredness for a few weeks; balance usually improves as the cyst shrinks
Rehabilitation Physiotherapy for balance, walking or limb weakness if needed

9. Living with haemangioblastoma

  • Keep to your scan schedule, especially if you have VHL
  • Know the warning signs: headaches, balance problems, weakness and vision changes
  • Talk to a genetic counsellor about testing your family and about family planning
  • Ask about physiotherapy after surgery to improve balance and strength
  • Connect with VHL patient organisations for information and support
  • Tell your team if you are planning pregnancy, especially if taking belzutifan

10. Frequently asked questions

Question Answer
Is a haemangioblastoma cancer? No. It is a benign tumour that does not spread, but it can cause serious symptoms
Do I have VHL? About 1 in 4 people with a haemangioblastoma do; genetic testing can tell
Will it come back after surgery? A single sporadic tumour rarely returns; in VHL, new tumours can develop
Can my children inherit it? Only if you have VHL; each child then has a 1 in 2 chance
Do all tumours need surgery? No. In VHL, many small tumours are simply monitored
What is belzutifan? A tablet that blocks HIF-2 alpha and can shrink VHL-related tumours
Why is my red blood cell count high? Some haemangioblastomas make erythropoietin, a hormone that stimulates red blood cell production; it usually returns to normal after the tumour is removed
Can I have children if I have VHL? Yes. Genetic counselling can explain the options, including testing during pregnancy or before IVF embryo transfer

11. Questions to ask your care team

  • Is my tumour sporadic, or should I be tested for VHL?
  • Does it need treatment now, or can it be monitored?
  • What are the risks of surgery in this location?
  • Would radiosurgery or belzutifan be suitable?
  • How often will I need scans and eye checks?
  • Should my family members be tested?

Resources

  1. Daniels, A.B. et al. (2023) ‘Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance’, Cancer, 129(19), pp. 2927-2940.
  2. Jonasch, E. et al. (2021) ‘Belzutifan for renal cell carcinoma in von Hippel-Lindau disease’, New England Journal of Medicine, 385(22), pp. 2036-2046.
  3. Lonser, R.R. et al. (2003) ‘von Hippel-Lindau disease’, Lancet, 361(9374), pp. 2059-2067.
  4. Lonser, R.R. et al. (2014) ‘Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease’, Journal of Neurosurgery, 120(5), pp. 1055-1062.
  5. Louis, D.N. et al. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
  6. Maher, E.R., Neumann, H.P. and Richard, S. (2011) ‘von Hippel-Lindau disease: a clinical and scientific review’, European Journal of Human Genetics, 19(6), pp. 617-623.
  7. Wanebo, J.E. et al. (2003) ‘The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease’, Journal of Neurosurgery, 98(1), pp. 82-94.
  8. National Cancer Institute (2026) Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq (Accessed: October 2026).
  9. National Cancer Institute (2026) Adult Central Nervous System Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.